4DN Stock Chart & Stats
€20.99
-€0.46(-2.21%)
At close: 4:00 PM EDT
€20.99
-€0.46(-2.21%)
Day’s Range― - ―
52-Week Range€12.42 - €23.47
Previous CloseN/A
Volume0.00
Average Volume (3M)12.00
Market Cap
€2.63B
Enterprise Value€4.14B
Total Cash (Recent Filing)€710.47M
Total Debt (Recent Filing)€27.50M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Nov 03, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.84
Shares Outstanding159,847,400
10 Day Avg. Volume0
30 Day Avg. Volume12
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)2.86
Price to Sales (P/S)0.00
P/FCF Ratio-6.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€32.15Price Target Upside53.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2
Revenue Forecast (FY)€34.64M
Bulls Say, Bears Say
Bulls Say
Validated CNS Transport PlatformAVLAYAH provides clinical and regulatory validation that Denali's transport vehicle platform can deliver a CNS-penetrant biologic through approval. This strengthens the potential for repeat use across additional lysosomal and neurodegenerative programs and supports a broader platform-based development strategy.
Early Commercial Access MomentumBroad early payer coverage reduces a key commercialization barrier for AVLAYAH and supports continued patient access as launch activity develops. Coverage across commercial and Medicaid channels can improve the durability of adoption and give Denali a stronger foundation for building commercial capabilities.
Strong Balance Sheet FlexibilityMore than $1.1 billion of pro forma cash gives Denali substantial funding capacity for commercialization, clinical development, and pipeline investment. This liquidity reduces immediate financing pressure and provides strategic flexibility while the company works to expand revenue and advance multiple programs.
Bears Say
Very Weak ProfitabilityThe large gap between current revenue and net loss shows that Denali remains economically dependent on investment in future products rather than self-funded operations. Persistently weak profitability limits earnings visibility and means commercial progress must accelerate materially to improve the underlying business model.
High Ongoing Cash BurnHeavy operating and free-cash-flow outflows consume capital at a rate that could remain significant while Denali commercializes AVLAYAH and funds its pipeline. Even with strong liquidity, sustained burn increases dependence on successful revenue growth and disciplined spending to preserve financial flexibility.
Clinical Timing And Competitive UncertaintyDelayed or distant clinical readouts defer important evidence on pipeline value and can extend the period before additional programs contribute to the business. At the same time, incumbent therapies, competing programs, and emerging gene therapies may pressure future differentiation, coverage, and adoption.
Denali Therapeutics News
4DN FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was €12.42 and its highest was €23.47 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is €2.63B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Nov 03, 2026 which is in 9 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Aug 06, 2026. The company reported -€0.607 earnings per share for the quarter, missing the consensus estimate of -€0.458 by -€0.149.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 159,847,400 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -€0.607 in its last earnings report, missing expectations of -€0.458. Following the earnings report the stock price went up 1.047%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Currently, no hedge funds are holding shares in DE:4DN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Denali Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€32.15 (53.18% Upside)
€32.15 (53.18% Upside)
Blogger Sentiment
Neutral
DE:4DN Sentiment 50%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth €96.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.93%
12-Months-Change
Fundamentals
Return on Equity
-55.27%
Trailing 12-Months
Asset Growth
-0.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Denali Therapeutics
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
4DN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call communicated a strong, constructive start to commercialization with meaningful early revenue ($3.6M), rapid payer progress (>50% commercial lives) and platform validation via AVLAYAH, supported by a robust pro forma cash position (> $1.1B) and multiple clinical programs advancing toward 2027 readouts. Near-term challenges include variability in revenue and patient initiation timing due to weight-based dosing and infusion logistics, limited disclosed patient-level metrics, some program timing shifts (DNL593), and competitive/coverage risks. On balance, the positive commercial and platform milestones materially outweigh the near-term operational and timing uncertainties.View all DE:4DN earnings summaries4DN Stock 12 Month Forecast
Average Price Target
€32.15
▲(53.18% Upside)